A comprehensive study of effective responses as well as resistant responses to a kidney cancer anti-PD-1 therapy found ...

Combination treatment with nivolumab and cabozantinib provides long-term benefits over sunitinib in patients with advanced RCC, according to final results from the CheckMate 9ER trial.

In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high ...

IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential ...

During a live event, participating oncologists discuss the role of ctDNA and molecular testing in muscle-invasive bladder ...

Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...

Conducted by leading digital insights consultancy Creation Healthcare, the research identified more than 80,000 posts on X (formerly Twitter) referencing prostate cancer, generated by more than 17,000 ...

The FDA has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence application (sBLA) for Opdivo and Yervoy ...

The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...

Patients with advanced melanoma that had spread to the brain were previously expected to survive for only 16 weeks.